Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared with placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer has not been determined.
Apalutamide for metastatic, castration-sensitive prostate cancer / Chi, Kim N; Agarwal, Neeraj; Bjartell, Anders; Chung, Byung Ha; Pereira de Santana Gomes, Andrea J; Given, Robert; Juárez Soto, Álvaro; Merseburger, Axel S; Özgüroğlu, Mustafa; Uemura, Hirotsugu; Ye, Dingwei; Deprince, Kris; Naini, Vahid; Li, Jinhui; Cheng, Shinta; Yu, Margaret K; Zhang, Ke; Larsen, Julie S; Mccarthy, Sharon; Chowdhury, Simon; Titan, Investigators; Sciarra, Alessandro. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 381:1(2019), pp. 13-24. [10.1056/NEJMoa1903307]
Apalutamide for metastatic, castration-sensitive prostate cancer
Sciarra AlessandroMembro del Collaboration Group
2019
Abstract
Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared with placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer has not been determined.| File | Dimensione | Formato | |
|---|---|---|---|
|
Kim_Apalutamide_2019.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
234.73 kB
Formato
Adobe PDF
|
234.73 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
